Evidence map›Paper›PMID 34825129›Full record

ArticleHSOA journal of alzheimer's & neurodegenerative diseases2021

Novel API Coated Catheter Removes Amyloid-β from Plasma of Patients with Alzheimer's Disease.

Rishi Raj Chhipa, Omkar Gandbhir, Hao Le, Sadhana Sankar, Pazhani Sundaram

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HSOA journal of alzheimer's & neurodegenerative diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Rishi Raj ChhipaRecombinant Technologies LLC, 1090 Meriden Waterbury Turnpike, Suite 1, Cheshire, Connecticut 06410, USA.
Omkar GandbhirRecombinant Technologies LLC, 1090 Meriden Waterbury Turnpike, Suite 1, Cheshire, Connecticut 06410, USA.
Hao LeRecombinant Technologies LLC, 1090 Meriden Waterbury Turnpike, Suite 1, Cheshire, Connecticut 06410, USA.
Sadhana SankarRecombinant Technologies LLC, 1090 Meriden Waterbury Turnpike, Suite 1, Cheshire, Connecticut 06410, USA.
Pazhani SundaramRecombinant Technologies LLC, 1090 Meriden Waterbury Turnpike, Suite 1, Cheshire, Connecticut 06410, USA.
Recombinant Technologies (United States) · US

Funding

Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer'sDiseaseR44AG057327 · NIA · RECOMBINANT TECHNOLOGIES, LLC · PI SUNDARAM, PAZHANI · 2019 to 2025
$3.4M
NIA NIH HHS R44 AG057327
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common cause of dementia, characterized by the deposition of Amyloid-beta (Aβ) plaques in the brain. We have previously developed Amytrap peptide (the active pharmacological ingredient, API) and linked it to a sepharose bead matrix by click chemistry to form Amytrapper matrix, which was able to bind and remove Aβ from human sera and plasma spiked with biotinylated Aβ42 (bio-Aβ42)

Indexed as

Alzheimer DiseaseAlzheimer’s TherapyAmyloidAmyloid beta-PeptidesAmyloid removalAmytrapper catheterExtracorporeal devicePlasmapheresis

Identifiers

PMID34825129
PMCPMC8612462
OpenAlexW3207813741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.